TerrAscend Corp.: Form 10-Q for the period ended Jun 30, 2022
Filed with the SEC on Aug 11, 2022 and accepted by EDGAR at Aug 11, 2022, 16:09 ET.
Management's discussion and analysis
As filed, 41,897 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following discussion and analysis of the Company's financial condition and results of operations should be read in conjunction with the Company's unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial information and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the Securities and Exchange Commission, or SEC, on March 17, 2022. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to the Company's plans and strategy for its business, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth under "Risk Factors" in the Company's Annual Report on Form 10-K, its actual results could differ materially from the results described in or implied by the "Cautionary Note Regarding Forward-Looking Statements" contained in this Quarterly Report on Form 10-Q and in the following discussion and analysis.
This Management’s Discussion and Analysis (“MD&A”) of the financial condition and results of operations of TerrAscend is for the three and six months ended June 30, 2022 and 2021 and the accompanying notes for each respective period.
Business Overview
TerrAscend is a leading North American cannabis operator with vertically integrated operations in Pennsylvania, New Jersey, and California, licensed cultivation and processing operations in Michigan and Maryland, and licensed processing operations in Canada. TerrAscend operates a chain of Apothecarium dispensary retail locations, as well as scaled cultivation, processing, and manufacturing facilities on both the east and west coasts of the United States. TerrAscend’s cultivation and manufacturing practices yield consistent, high-quality cannabis, providing industry-leading product selection to both the medical and legal adult-use market. Notwithstanding various states in the US which have implemented medical marijuana laws, or which have otherwise legalized the use of cannabis, the use of cannabis remains illegal under US federal law for any purpose, by way of the CSA.
TerrAscend operates under one operating segment which is the cultivation, production and sale of cannabis products.
TerrAscend’s portfolio of operating businesses and brands include:
- Gage Growth Corp. ("Gage"), a cultivator and processor in Michigan
- Ilera Healthcare, a vertically integrated cannabis cultivator, processor and dispensary operator in Pennsylvania;
- TerrAscend NJ LLC, a majority owned subsidiary that holds a permit to operate up to three alternative treatment centers in New Jersey with the ability to cultivate and process;
- The Apothecarium, consisting of retail dispensaries in California, Pennsylvania and New Jersey;
- Valhalla Confections, a provider of premium edible products;
- State Flower, a California-based cannabis producer operating a licensed cultivation facility in San Francisco, California;
- HMS Health, LLC and HMS Processing, LLC, a producer and seller of dried flower and oil products for the wholesale medical cannabis market in Maryland;
- TerrAscend Canada Inc., a Licensed Producer (as such term is defined in the Cannabis Act) of cannabis, with its current principal business activities including processing and sale of cannabis flower and oil products in Canada;
- Cookies Canada, the operator of a minority owned retail cannabis dispensary in Toronto, Canada; and
- Arise Bioscience, a manufacturer and distributor of hemp-derived products, located in Boca Raton, Florida.
Objective
TerrAscend's MD&A is designed to provide information about its financial condition and results of operations from management's perspective. It includes relevant components of TerrAscend's financial condition and current and long-term liquidity. Primary revenue drivers include the manufacture, distribution, and sale of medical and adult-use cannabis products where permitted. TerrAscend's primary obligations are related to compliance with state and federal regulators, as applicable. TerrAscend's primary sources of capital have been through the issuance of equity securities or debt. TerrAscend's objective is to discuss how all these factors have affected our historical results and, where applicable, how it expects these factors to impact its future results and future liquidity.
Results from Operations- Three months ended June 30, 2022 and June 30, 2021
The following tables represent the Company’s results from operations for the three months ended June 30, 2022 and 2021.
Revenue, net
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Revenue | $65,367 | $61,977 |
| Excise and cultivation taxes | (563) | (3,254) |
| Revenue, net | $64,804 | $58,723 |
| $ change | $6,081 | |
| % change | 10% |
The increase in net revenue at June 30, 2022 as compared to June 30, 2021 was due to an increase in retail revenue of $25,586 from $22,393 for the three months ended June 30, 2021 to $47,979 for the three months ended June 30, 2022. The increase in revenue is mainly due to adult use sales in New Jersey which commenced during the three months ended June 30, 2022, as well as the acquisition of Gage (the "Gage Acquisition") in Michigan in March 2022. Retail dispensaries increased from thirteen at June 30, 2021 to twenty-six at June 30, 2022.
The increase is partially offset by the decrease of $19,505 in wholesale revenue from $36,330 at June 30, 2021 to $16,825 for the three months ended June 30, 2022 which was mainly related to the operational reconfiguration of the Company's cultivation facility in Pennsylvania.
Cost of Sales
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Cost of sales | $34,389 | $23,773 |
| Impairment and write downs of inventory | 7,422 | 115 |
| Total cost of sales | $41,811 | $23,888 |
| $ change | $17,923 | |
| % change | 75% | |
| Cost of sales as a % of revenue | 65% | 41% |
The increase in cost of sales for the three months ended June 30, 2022 as compared to the three months ended June 30, 2021 was driven mainly by the Gage Acquisition, as well as an increase in New Jersey due to the increase in adult use sales which commenced during the three months ended June 30, 2022. The increase in cost of sales as a percentage of revenue was due to lower volumes in Pennsylvania leading to under-absorption, primarily related to lower wholesale flower sales, as well as operational challenges at the Company's cultivation facility in Frederick, Maryland as the Company transitions to its Hagerstown location.
In addition, management wrote down its inventory by $7,422 and $115 for the three months ended June 30, 2022 and 2021, respectively. The inventory write-downs in the current year period were mainly due to the write down of inventory to lower of cost or market which was related to the aforementioned operational reconfiguration of its cultivation facility in Pennsylvania, write downs of inventory related to a recall by the Pennsylvania Department of Health of certain vape products produced by the Company, as well as inventory in Canada that the Company deemed unsaleable. On February 4, 2022, more than 500 vape products were recalled by the Pennsylvania's Department of Health, including several of the Company's SKUs. As a result of the recall, the Company wrote off $1,071 of inventory during the three months ended June 30, 2022. The inventory write-downs in the prior year period were related to inventory that the Company deemed unsaleable.
General and Administrative Expense (G&A)
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| General and administrative expense | $33,981 | $20,750 |
| $ change | $13,231 | |
| % change | 64% | |
| G&A excluding share-based compensation | $29,518 | $16,102 |
| G&A excluding share-based compensation as a % of revenue | 46% | 27% |
25
The increase in G&A expenses was primarily a result of increased salaries and wages of $6,178, sales and marketing expense of $3,859, and office and general expense of $2,673, which is primarily a result of the Gage Acquisition in March 2022.
Amortization and Depreciation Expense
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Amortization and depreciation | $3,016 | $1,844 |
| $ change | $1,172 | |
| % change | 64% |
The increase in amortization and depreciation expense for the three months ended June 30, 2022 as compared to the three months ended June 30, 2021 is primarily due to the Gage Acquisition during March 2022. The company acquired intangible assets including cultivation and processing licenses, as well as retail licenses, which are amortized over a 15 year period. The fair value of the cultivation and processing and retail licenses at acquisition were $77,198 and $53,321, respectively.
(Gain) loss on fair value of warrants and purchase option derivative asset
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| (Gain) loss on fair value of warrants and purchase option derivative asset | $(47,345) | $19,891 |
| $ change | $(67,236) | |
| % change | -338% |
The warrant liability has been remeasured to fair value at June 30, 2022 using the Black Scholes model. The Company recognized a gain during the three months ended June 30, 2022 as a result of the reduction of the Company's share price from March 31, 2021 as compared to June 30, 2022, as well as from warrants exercised during the three months ended June 30, 2022. The combined impact resulted in a gain on fair value of warrants of $47,845.
For the three months ended June 30, 2022, the purchase option derivative asset related to the option to purchase an additional 6.25% ownership of the Company's New Jersey partnership, was remeasured using the Monte Carlo simulation model and resulted in a loss of $500.
During the three months ended June 30, 2021, the Company recognized a loss on fair value of warrants of $19,891 as a result of the increase in the Company's share price from December 31, 2020 to June 30, 2021 as well as warrants exercised during the three months ended June 30, 2021.
Finance and other expenses
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Finance and other expenses | $13,902 | $8,919 |
| $ change | $4,983 | |
| % change | 56% |
The increase in finance expense for the three months ended June 30, 2022 as compared to the three months ended June 30, 2021 is primarily due to interest expense recognized on the loans acquired as part of the Gage Acquisition, as well as a loss recognized on disposal of fixed assets of $981 related to lights at the Pennsylvania cultivation facility which were discarded during the three months ended June 30, 2022.
Transaction and restructuring costs
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Transaction and restructuring costs | $627 | $432 |
| $ change | $195 | |
| % change | 45% |
The increase in transaction and restructuring costs for the three months ended June 30, 2022 as compared to the three months ended June 30, 2021 was primarily due to work done for Sarbanes Oxley implementation during the three months ended June 30, 2022.
Impairment of goodwill
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Impairment of goodwill | $- | $5,007 |
| $ change | $(5,007) | |
| % change | -100% |
The impairment of goodwill for the three months ended June 30, 2021 was related to the Company's Florida reporting unit as the Company determined that the estimated cash flows of its Arise business did not support the carrying value of the intangible assets and goodwill. As a result, the Company recorded impairment to reduce the balance of goodwill at its Florida reporting unit to $nil.
Impairment of intangible assets
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Impairment of intangible assets | $- | $3,633 |
| $ change | $(3,633) | |
| % change | -100% |
The impairment recorded during the three months ended June 30, 2021 relates to the write-off of intellectual property at the Company's Arise business.
Unrealized and realized foreign exchange loss
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Unrealized and realized foreign exchange loss | $(306) | $3,055 |
| $ change | $(3,361) | |
| % change | -110% |
The decrease in unrealized foreign exchange loss for the three months ended June 30, 2022 as compared to the three months ended June 30, 2021 is a result of the remeasurement of USD denominated cash and other assets recorded in C$ functional currency at the Company’s Canadian operations.
Unrealized and realized gain on investments
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Unrealized and realized loss (gain) on investments | $234 | $(5,964) |
| $ change | $6,198 | |
| % change | -104% |
The loss on investment during the three months ended June 30, 2022 is related to the revaluation of the investments acquired through the Gage Acquisition. The gain on investment during the three months ended June 30, 2021 relates to the acquisition of the remaining 90% investment in Guadco LLC and KCR Holdings LLC on April 30, 2021.
Provision for income taxes
| For the Three Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Provision for income taxes | $4,688 | $6,937 |
| $ change | $(2,249) | |
| % change | -32% |
The decrease in provision for income taxes for the three months ended June 30, 2022 as compared to the three months ended June 30, 2021 was due to the decline in revenue and associated decline in gross profit, mainly related to the operational reconfiguration of the Company's cultivation facility in Pennsylvania.
Results from Operations- Six months ended June 30, 2022 and June 30, 2021
The following tables represent the Company’s results from operations for the six months ended June 30, 2022 and 2021.
Revenue, net
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Revenue | $115,812 | $118,473 |
| Excise and cultivation taxes | (1,349) | (6,396) |
| Revenue, net | $114,463 | $112,077 |
| $ change | $2,386 | |
| % change | 2% |
The increase in net revenue at June 30, 2022 as compared to June 30, 2021 was due to an increase in retail revenue of $36,334 from $37,363 for the six months ended June 30, 2021 to $73,697 for the six months ended June 30, 2022. The increase in revenue is mainly due to adult use sales in New Jersey which commenced during the six months ended June 30, 2022, as well as the Gage Acquisition. Retail dispensaries increased from thirteen at June 30, 2021 to twenty-six at June 30, 2022.
This increase is partially offset by a decrease of $33,948 in wholesale revenue from $74,714 for the six months ended June 30, 2021 to $40,766 for the six months ended June 30, 2022, which was mainly related to a decline in the Canada business, as well as the operational reconfiguration of the Company's cultivation facility in Pennsylvania, as well as the aforementioned vape recall. As a result of the recall, the Company recorded sales returns of $1,040 during the six months ended June 30, 2022.
Cost of Sales
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Cost of sales | $67,835 | $41,601 |
| Impairment and write downs of inventory | 8,495 | 699 |
| Total cost of sales | $76,330 | $42,300 |
| $ change | $34,030 | |
| % change | 80% | |
| Cost of sales as a % of revenue | 67% | 38% |
The increase in cost of sales for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 was driven mainly by the Gage Acquisition, as well as an increase in New Jersey due to adult use sales which commenced during the six months ended June 30, 2022. The increase in cost of sales as a percentage of revenue was primarily due to lower wholesale flower sales volume in Pennsylvania leading to under-absorption, and unfavorable mix, primarily related to lower Gage bulk wholesale sales at the end of the first quarter.
In addition, management wrote down its inventory by $8,495 and $699 for the six months ended June 30, 2022 and 2021, respectively. The inventory write-downs in the current year period were mainly due to the write down of inventory to lower of cost or market which was related to the Company's operational reconfiguration of its cultivation facility in Pennsylvania, write downs of inventory related to the vape recall, as well as inventory in Canada that the Company deemed unsaleable. As a result of the recall, the Company wrote off $1,925 of inventory during the six months ended June 30, 2022. The inventory write-downs in the prior year period were related to inventory that the Company deemed unsaleable.
General and Administrative Expense (G&A)
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| General and administrative expense | $56,533 | $41,142 |
| $ change | $15,391 | |
| % change | 37% | |
| G&A excluding share-based compensation | $48,714 | $32,927 |
| G&A excluding share-based compensation as a % of revenue | 43% | 29% |
The increase in G&A expenses was primarily a result of increased salaries and wages of $7,815, sales and marketing expense of $4,464, and office and general expense of $2,384, which is primarily a result of the Gage Acquisition.
Amortization and Depreciation Expense
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Amortization and depreciation | $5,634 | $3,717 |
| $ change | $1,917 | |
| % change | 52% |
28
The increase in amortization and depreciation expense for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 is primarily due to the Gage Acquisition. The Company acquired intangible assets including cultivation and processing licenses, as well as retail licenses, which are amortized over a 15 year period. The fair value of the cultivation and processing licenses and retail licenses at acquisition were $77,198 and $53,321, respectively.
Revaluation of contingent consideration
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Revaluation of contingent consideration | $153 | $2,990 |
| $ change | $(2,837) | |
| % change | -95% |
The decrease in the revaluation of contingent consideration for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 is a result of a reduction in the liability as compared to June 30, 2021 due to payments for the earnout of Ilera of $29,668, and State Flower of $7,040 made subsequent to June 30, 2021, reducing the amount outstanding. This decrease is partially offset by the accretion of the contingent consideration payable for KCR, which are recorded at the present value of future payments upon initial recognition.
(Gain) loss on fair value of warrants and purchase option derivative asset
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| (Gain) loss on fair value of warrants and purchase option derivative asset | $(53,058) | $25,301 |
| $ change | $(78,359) | |
| % change | -310% |
The warrant liabilities have been remeasured to fair value at June 30, 2022 using the Black Scholes model. The Company recognized a gain during the six months ended June 30, 2022 as a result of the reduction of the Company's share price from December 31, 2021 as compared to June 30, 2022, as well as from warrants exercised during the six months ended June 30, 2022. The combined impact resulted in a gain on fair value of warrants of $53,876.
For the six months ended June 30, 2022, the purchase option derivative asset related to the option to purchase an additional 6.25% ownership of the Company's New Jersey partnership, was remeasured using the Monte Carlo simulation model and resulted in a loss of $818.
During the six months ended June 30, 2021 the Company recognized a loss on fair value of warrants of $25,301 as a result of the increase in the Company's share price from December 31, 2020 to June 30, 2021 as well as warrants exercised during the six months ended June 30, 2021.
Finance and other expenses
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Finance and other expenses | $20,758 | $15,309 |
| $ change | $5,449 | |
| % change | 36% |
The increase in finance expense for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 is primarily due to interest expense recognized on the loans acquired as part of the Gage Acquisition.
Transaction and restructuring costs
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Transaction and restructuring costs | $1,242 | $432 |
| $ change | $810 | |
| % change | 188% |
The increase in transaction and restructuring costs for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 was primarily due to the Gage Acquisition, as well as work done for Sarbanes Oxley implementation.
Impairment of goodwill
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Impairment of goodwill | $- | $5,007 |
| $ change | $(5,007) | |
| % change | -100% |
The impairment of goodwill for the six months ended June 30, 2021 was related to the Company's Florida reporting unit as the Company determined that the estimated cash flows of its Arise business did not support the carrying value of the intangible assets and goodwill. As a result, the Company recorded impairment to reduce the balance of goodwill at its Florida reporting unit to $nil.
Impairment of intangible assets
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Impairment of intangible assets | $- | $3,633 |
| $ change | $(3,633) | |
| % change | -100% |
The impairment recorded during the six months ended June 30, 2021 relates to the write-off of intellectual property at the Company's Arise business.
Unrealized and realized foreign exchange loss
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Unrealized and realized foreign exchange loss | $50 | $5,838 |
| $ change | $(5,788) | |
| % change | -99% |
The decrease in unrealized foreign exchange loss for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 is a result of the remeasurement of USD denominated cash and other assets recorded in C$ functional currency at the Company’s Canadian operations.
Unrealized and realized gain on investments
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Unrealized and realized loss (gain) on investments | $234 | $(6,192) |
| $ change | $6,426 | |
| % change | -104% |
The loss on investment during the six months ended June 30, 2022 is related to the revaluation of the investments acquired through the Gage Acquisition. The gain on investment during the six months ended June 30, 2021 relates to the acquisition of the remaining 90% investment in Guadco LLC and KCR Holdings LLC on April 30, 2021.
Provision for income taxes
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Provision for income taxes | $8,431 | $16,373 |
| $ change | $(7,942) | |
| % change | -49% |
The decrease in provision for income taxes for the six months ended June 30, 2022 as compared to the six months ended June 30, 2021 was due to the decline in revenue and associated decline in gross profit, mainly related to the operational reconfiguration of the Company's cultivation facility in Pennsylvania, as well as the vape recall by the Pennsylvania Department of Health.
Liquidity and Capital Resources
| June 30, 2022 $$ | December 31, 2021 | |
|---|---|---|
| Cash and cash equivalents | 48,426 | 79,642 |
| Current assets | 137,318 | 143,221 |
| Non-current assets | 871,299 | 438,713 |
| Current liabilities | 140,403 | 61,044 |
| Non-current liabilities | 323,246 | 291,936 |
| Working capital | (3,085) | 82,177 |
| Total shareholders' equity | 544,968 | 228,954 |
The calculation of working capital provides additional information and is not defined under GAAP. The Company defines working capital as current assets less current liabilities. This measure should not be considered in isolation or as a substitute for any standardized measure under GAAP.
At June 30, 2022, TerrAscend had cash and cash equivalents of $48,426, which is sufficient to fund the Company’s ongoing operations. Any additional future requirements will be funded through the following sources of capital:
- Cash from ongoing operations.
- Market offerings.
- Debt - the Company may seek to obtain additional debt from additional creditors.
- Sale leaseback - the Company may seek to sell and lease back its capital properties.
- Exercise of options and warrants - the Company would receive funds from exercise of options and warrants from the holders of such securities in the event they are exercised.
The Company’s objective with respect to its capital management is to ensure it has sufficient cash resources to maintain its ongoing operations and finance its research and development activities, corporate and administration expenses, working capital and overall capital expenditures. Since inception, the Company has primarily financed its liquidity needs through the issuance of shares and utilization of borrowings.
The Company has $280,136 in principal amounts of loans payable at June 30, 2022. Of this amount, $68,955 are due within the next twelve months. The Company has entered into operating leases for certain premises and offices for which it owes monthly lease payments.
In addition, the Company's undiscounted contingent consideration payable is $10,734 at June 30, 2022. The contingent consideration payable relates to the Company's business acquisitions of The Apothecarium, State Flower, and KCR. Contingent consideration is based upon the potential earnout of the underlying business unit and is measured at fair value using a projection model for the business and the formulaic structure for determining the consideration under the agreement. The contingent consideration is revalued at the end of each reporting period.
The Company expects that its cash on hand and cash flows from operations, along with financing transactions, will be adequate to meet its capital requirements and operational needs for at least the next 12 months.
Cash Flows
Cash flows from operating activities
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Net cash used in operating activities | $(34,976) | $(10,076) |
The increase in cash used in operating activities for the six months ended June 30, 2022 is primarily due to an increase in loss from operations to $24,034 from a profit of $24,918 in the prior year period, as well as changes in working capital items of $16,081.
Cash flows from investing activities
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Net cash provided used in investing activities | $(39) | $(63,387) |
The net cash used in investing activities for the six months ended June 30, 2022 primarily relates to investments in property and equipment of $12,500 and deposits for property and equipment of $10,036, primarily related to the buildout of a cultivation site in Maryland, continuing renovations at the Company's Pennsylvania cultivation site, as well as the continued buildout of the Company's Lodi alternative treatment center in New Jersey. Additionally, the Company had investments in intangible assets of $1,330, primarily related to adult use licenses in New Jersey. The cash used in investing activities is offset by cash inflows of $24,716 related to the cash acquired through the Gage Acquisition.
In comparison, the net cash used in investing activities for the six months ended June 30, 2021 primarily relates to cash consideration paid for the acquisitions of KCR and HMS totaling $42,736. Additionally, the Company had investments in property and equipment of $10,856 primarily related to the buildout of the New Jersey operations and expansions in Pennsylvania cultivation and $10,583 related to deposits paid for expansion of the cultivation premises in Pennsylvania.
Cash flows from financing activities
| For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|
| Net cash provided by financing activities | $8,781 | $168,507 |
During the six months ended June 30, 2022, 7,989,436 Common Share warrants were exercised for total proceeds of $23,797 and 88,015 stock options were exercised for total gross proceeds of $361. The cash provided by financing activities was offset by payments of contingent consideration related to the acquisition of State Flower of $6,630, loan principal payments of $5,203, loan amendment fee paid on the modification of the Ilera term loan of $1,200, and tax distributions paid on behalf of the partners of the New Jersey operations of $1,436.
Net cash provided by financing activities for the six months ended June 30, 2021, was mainly the result of the private placement on January 28, 2021, in which the Company issued 18,115,656 Common Shares at a price of $9.64 (C$12.35) per Common Share for total proceeds of $173,477, net of share issuance costs of $1,643. Additionally, during the six months ended June 30, 2021, 2,590,178 Common Share warrants were exercised for total proceeds of $6,777 and 699,009 stock options were exercised at $0.67-$6.93 (C$0.85-$8.52) per unit for total gross proceeds of $2,385. In addition, 1,900 preferred share warrants were exercised at $3,000 per unit for total gross proceeds of $3,759. The cash provided by financing activities was offset by payments of contingent consideration related to the acquisition of Ilera of $18,274.
Reconciliation of Non-GAAP Measures
In addition to reporting the financial results in accordance with GAAP, the Company reports certain financial results that differ from what is reported under GAAP. Non-GAAP measures used by management do not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company believes that certain investors and analysts use these measures to measure a company's ability to meet other payment obligations or as a common measurement to value companies in the cannabis industry, and the Company calculates Adjusted gross profit as gross profit adjusted for certain material non-cash items and Adjusted EBITDA as EBITDA adjusted for material non-cash items and certain other adjustments management believes are not reflective of the ongoing operations and performance. Such information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with GAAP. The Company believes this definition is a useful measure to assess the performance of the Company as it provides more meaningful operating results by excluding the effects of expenses that are not reflective of the Company's underlying business performance and other one-time non-recurring expenses.
The table below reconciles net loss to EBITDA and Adjusted EBITDA for the three and six months ended June 30, 2022 and 2021.
| Notes | For the Three Months Ended June 30, 2022 | June 30, 2021 | For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|---|---|---|
| Net income (loss) | $14,162 | $(29,662) | $(1,844) | $(43,773) | |
| Add (deduct) the impact of: | |||||
| Provision for income taxes | 4,688 | 6,937 | 8,431 | 16,373 | |
| Finance expenses | 9,427 | 6,424 | 16,125 | 11,783 | |
| Amortization and depreciation | 7,046 | 3,529 | 12,131 | 7,050 | |
| EBITDA | (a) | 35,323 | (12,772) | 34,843 | (8,567) |
| Add (deduct) the impact of: | |||||
| Relief of fair value upon acquisition | (b) | 549 | 567 | 2,355 | 567 |
| Non-cash write downs of inventory | (c) | 5,894 | 449 | 5,894 | 449 |
| Vape recall | (d) | 1,071 | - | 2,965 | — |
| Share-based compensation | (e) | 4,463 | 4,648 | 7,819 | 8,215 |
| Impairment of goodwill and intangible assets | (f) | - | 8,640 | - | 8,640 |
| Loss on disposal of fixed assets | (g) | 929 | 36 | 929 | 36 |
| Revaluation of contingent consideration | (h) | 34 | (7) | 153 | 2,990 |
| Restructuring costs and executive severance | (i) | - | 467 | - | 467 |
| Legal settlements | (j) | - | 740 | — | 2,121 |
| Other one-time items | (k) | 924 | 860 | 2,898 | 1,122 |
| (Gain) loss on fair value of warrants and purchase option derivative asset | (l) | (47,345) | 19,891 | (53,058) | 25,301 |
| Indemnification asset release | (m) | 3,998 | 2,599 | 3,973 | 3,796 |
| Unrealized and realized loss (gain) on investments | (n) | 234 | (5,964) | 234 | (6,192) |
| Unrealized and realized foreign exchange loss | (o) | (306) | 3,055 | 50 | 5,838 |
| Adjusted EBITDA | $5,768 | $23,209 | $9,055 | $44,783 |
The table below reconciles gross profit to adjusted gross profit for the three and six months ended June 30, 2022 and 2021.
| Notes | For the Three Months Ended June 30, 2022 | June 30, 2021 | For the Six Months Ended June 30, 2022 | June 30, 2021 | |
|---|---|---|---|---|---|
| Gross profit | $22,993 | $34,835 | $38,133 | $69,777 | |
| Add (deduct) the impact of: | |||||
| Relief of fair value upon acquisition | (b) | 549 | 567 | 2,355 | 567 |
| Non-cash write downs of inventory | (c) | 5,894 | 449 | 5,894 | 449 |
| Vape recall | (d) | 1,071 | - | 2,965 | - |
| Accelerated depreciation | (p) | - | - | 238 | - |
| $30,507 | $35,851 | $49,585 | $70,793 |
(a) EBITDA is a non-GAAP measure and is calculated as earnings before interest, tax, depreciation and amortization.
(b) In connection with the Company's acquisitions, inventory was acquired at fair value, which included a markup or markdown for profit. Recording inventory at fair value in purchase accounting has the effect of increasing or decreasing inventory and thereby increasing or decreasing cost of sales as compared to the amounts the Company would have recognized if the inventory was sold through at cost. The write-up or down of acquired inventory represents the incremental cost of sales that were recorded during purchase accounting.
(c) Represents inventory write downs outside of the normal course of operations. These inventory write-downs were related to the the write down of aged inventory to lower of cost or market which was related to the Company's operational reconfiguration of its cultivation facility in Pennsylvania.
(d) On February 4, 2022, more than 500 vape products were recalled by the Pennsylvania's Department of Health, including several of the Company's SKUs. As a result of the recall the Company recorded sales returns of $nil and $1,040 and write-downs of inventory of $1,071 and $1,925 for the three and six months ended June 30, 2022, respectively.
(e) Represents non-cash share-based compensation expense.
(f) Represents impairment charges taken on the Company's intangible assets and goodwill.
(g) Represents loss taken on write-down of property and equipment.
(h) Represents the revaluation of the Company’s contingent consideration liabilities.
(i) Represents costs associated with executive severance and restructuring of business units.
(j) Represents one-time legal settlement charges.
(k) Includes one-time fees incurred in connection with the Company’s acquisitions, such as expenses related to professional fees, consulting, legal and accounting, that would otherwise not have been incurred. In addition, includes one-time charges for Sarbanes Oxley implementation, as well as work completed in preparation of becoming a US filer. These fees are not indicative of the Company’s ongoing costs.
(l) Represents the (gain) loss on fair value of warrants, including effects of the foreign exchange of the US denominated preferred share warrants, as well as the revaluation of the fair value of the purchase option derivative asset.
(m) Represents the reduction to the indemnification asset related to the Apothecarium tax audit settlement and statute expirations for tax years ended September 30, 2014 and September 30, 2015.
(n) Represents unrealized and realized loss (gain) on fair value changes on strategic investments.
(o) Represents the remeasurement of USD denominated cash and other assets recorded in C$ functional currency.
(p) Represents accelerated depreciation taken in Maryland due to the move of the cultivation facility from Frederick and Hagerstown.
The decrease in Adjusted EBITDA for the three and six months ended June 30, 2022 compared to the three and six months ended June 30, 2021 was primarily due to lower volume and resulting gross margin compression in Pennsylvania related to the Company's operational reconfiguration of its cultivation facility in Pennsylvania.
Pending and Subsequent Transactions
On April 8, 2022, the Company entered into a definitive agreement to acquire Allegany Medical Marijuana Dispensary ("AMMD"), a medical dispensary in Maryland from Moose Curve Holdings, LLC. Under the terms of the agreement, the Company will acquire 100% equity interest in AMMD for total consideration of $10,000 in cash, in addition to acquiring the real estate for $1,700. The transaction is subject to customary closing conditions and regulatory approvals. The Company intends to rebrand the 8,000 square foot dispensary as The Apothecarium.
On April 14, 2022, the Company entered into a definitive agreement to acquire KISA Enterprises MI, LLC and KISA Holdings, LLC ("Pinnacle"), a dispensary operator in Michigan, and related real estate, for total consideration of $28,500, payable in cash, two promissory notes in an aggregate amount of $10,000, and stock. The transaction includes six retail dispensary licenses, five of which are currently operational and located in the cities of Addison, Buchanana, Camden, Edmore, and Morenci, Michigan. The Company intends to rebrand each of the dispensaries under either the Gage or Cookies retail brand. This transaction is pending approval.
Changes in or Adoption of Accounting Principles
Information regarding the Company's adoption of new accounting and reporting standards is discussed in Note 2 to the accompanying condensed consolidated financial statements.
Descriptions of the recently issued and adopted accounting principles are included in Item 1. "Financial Statements" in Note 1, Summary of Significant Accounting Policies, to the Condensed Consolidated Financial Statements.
Critical Accounting Policies and Estimates
The condensed consolidated financial statements have been prepared in accordance with GAAP. The preparation of these condensed consolidated financial statements require us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. The Company bases its estimates on historical experience and assumptions on an ongoing basis. Actual results may differ from these estimates. To the extent that there are material differences between these estimates and actual results, the Company's future financial statements will be affected. There have been no significant changes to the critical accounting policies and estimates from the information provided in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operation," included in the Annual Report on Form 10-K for the year ended December 31, 2021, which was filed on March 17, 2022.
Emerging Growth Company Status
The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that the Company (i) is no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, the condensed consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
The Company will remain an emerging growth company until the earlier to occur of: (i) the last day of the fiscal year (a) following the fifth anniversary of the completion of the IPO, (b) in which we have total annual gross revenue of $1.07 billion or more, or (c) in which the Company is deemed to be a large accelerated filer, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th; and (ii) the date on which the Company has issued more than $1.0 billion in non-convertible debt during the prior three-year period.
Market risk
As filed, 241 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
There have been no material changes in the Company's primary risk exposures or management of market risks for the quarter ended June 30, 2022 from those disclosed in its Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Controls and procedures
As filed, 2,047 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
The Company's management, with the participation of its President and Chief Financial Officer, has evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q. Based upon that evaluation, the President and Chief Financial Officer concluded that, as of June 30, 2022 the Company's disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to the Company's management, including its President and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There were no changes in the Company's internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the six months ended June 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Limitations on Effectiveness of Controls and Procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
Risk factors
As filed, 488 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Investing in the Company's common stock involves a high degree of risk. For a detailed discussion of the risks that affect the Company's business, please refer to the section titled “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 17, 2022. There have been no material changes to the Company's risk factors as previously disclosed in its Annual Report on Form 10-K for the year ended December 31, 2021.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-04-01 to 2022-06-30 | $64.8m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2022-01-01 to 2022-06-30 | $114.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2022-04-01 to 2022-06-30 | $41.8m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2022-01-01 to 2022-06-30 | $76.3m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2022-04-01 to 2022-06-30 | $23.0m | us-gaap:GrossProfit |
| Gross profit | 6 months2022-01-01 to 2022-06-30 | $38.1m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2022-04-01 to 2022-06-30 | $34.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2022-01-01 to 2022-06-30 | $56.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-04-01 to 2022-06-30 | −$14.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2022-01-01 to 2022-06-30 | −$24.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-04-01 to 2022-06-30 | $4.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2022-01-01 to 2022-06-30 | $8.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-04-01 to 2022-06-30 | $13.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months2022-01-01 to 2022-06-30 | −$3.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-04-01 to 2022-06-30 | $0.05 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2022-01-01 to 2022-06-30 | −$0.01 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-04-01 to 2022-06-30 | $0.05 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2022-01-01 to 2022-06-30 | −$0.01 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-04-01 to 2022-06-30 | 257,883,711,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2022-01-01 to 2022-06-30 | 231,829,926,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2022-01-01 to 2022-06-30 | −$35.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2022-01-01 to 2022-06-30 | $12.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2022-06-30 | $48.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-06-30 | $137.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-06-30 | $1.01bn | us-gaap:Assets |
| Current liabilities | At period end2022-06-30 | $140.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-06-30 | $463.6m | us-gaap:Liabilities |
| Long-term debt | At period end2022-06-30 | $280.1m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2022-06-30 | $545.0m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0000950170-22-016864. Last ingested by Listed: Nov 5, 2026, 17:55 ET. Listed shows no prices and gives no investment advice.